
Takeda-6d
CAS No. 1125632-93-0
Takeda-6d( —— )
Catalog No. M27581 CAS No. 1125632-93-0
Takeda-6d is a novel, potent DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with IC50 of 7.0 nM and 2.2 nM, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 206 | Get Quote |
![]() ![]() |
5MG | 304 | Get Quote |
![]() ![]() |
10MG | 448 | Get Quote |
![]() ![]() |
25MG | 731 | Get Quote |
![]() ![]() |
50MG | 1017 | Get Quote |
![]() ![]() |
100MG | 1368 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameTakeda-6d
-
NoteResearch use only, not for human use.
-
Brief DescriptionTakeda-6d is a novel, potent DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with IC50 of 7.0 nM and 2.2 nM, respectively.
-
DescriptionTakeda-6d is a novel, potent DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with IC50 of 7.0 nM and 2.2 nM, respectively.
-
In Vitro——
-
In VivoTakeda-6D (compound 6d) (10 mg/kg, Orally, once) shows sufficient oral bioavailability (F = 70.5%) in rats.Takeda-6D (0-10 mg/kg, Orally, once) significantly decreases phosphorylation levels of ERK1/24 h after oral administration in an A375 (BRAFV600E mutant) human melanoma xenograft model in rats.Takeda-6D (10 mg/kg, Orally, twice daily for 2 weeks) shows tumor regression with T/Cof ?7.0% without severe toxicity, and this tumor regression should include the efficacy based on the antiangiogenesis potency and BRAF inhibitory activity.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetVEGFR
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1125632-93-0
-
Formula Weight547.99
-
Molecular FormulaC27H19ClFN5O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN#CC1(CC1)c1cccc(C(Nc(cc(cc2)Oc(cc3)nc4c3nc(NC(C3CC3)=O)s4)c2F)=O)c1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Finn PJ, Sun L, Nampalli S, Xiao H, Nelson JR, Mamone JA, Grossmann G, Flick PK, Fuller CW, Kumar S. Synthesis and application of charge-modified dye-labeled dideoxynucleoside-5'-triphosphates to 'direct-load' DNA sequencing. Nucleic Acids Res. 2002 Jul 1;30(13):2877-85.
molnova catalog



related products
-
Parsatuzumab
Parsatuzumab (RG 7414) is a humanized monoclonal antibody targeting EGFL7, which is also used as an immunomodulator.
-
CL-387785
CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of EGFR(IC50: 370+/-120 pM);is able to overcome resistance caused by the T790M mutation on a functional level.
-
Cabozantinib (S-mala...
Cabozantinib (XL184) is a potent, multi-kinase inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.